Abstract:Xue Fang Li, 1 Shi Rong Liu, 2 Jin Jin Li, 1 Ning Liu, 2 Hui Min Li, 3 An Ning Ge, 4 Liang Liang Wang, 5 Xie Min Dong, 1 Hui Wang, 1 Ju Liu, 1 Lin Zhang, 1 Hao Dong Zhang, 1 Wei Gou 1 1 Department of Metabolic Liver Disease, Qingdao Sixth People's Hospital, Qingdao City, Shandong Province, People's Republic of China; 2 Infectious Diseases department, People's Hospital of Qu fu City, Qufu City, Shandong Province, People's Republic of China; 3 Infection Department, Jiaozhou Branch of Shanghai East Hospital Tongji University, Qingdao City, Shandong Province, People's Republic of China; 4 Department of Infectious Diseases, People's Hospital of Rizhao City, Rizhao City, Shandong Province, People's Republic of China; 5 Medical Intervention Department, Qingdao Sixth People's Hospital, Qingdao City, Shandong Province, People's Republic of China Correspondence: Wei Gou, Department of Metabolic Liver Disease, Qingdao Sixth People's Hospital, Qingdao City, Shandong Province, People's Republic of China, Tel +86-15666687727, Fax +86-532-81636699, Email Objective: To investigate the risk factors for the development of portal hypertension in patients with decompensated cirrhosis and analyze their prognosis. Methods: Patients with decompensated cirrhosis who were admitted to our hospital and Qu fu People's Hospital from June 2022 to June 2023 were included in this study. Among them, there were 45 male and 15 female patients, with a median age of 56 (range: 35– 77) years. A comparative analysis was performed between Group A (hepatic venous pressure gradient, HVPG < 16 mmHg) and Group B (HVPG ≥ 16 mmHg) patients, along with various clinical outcomes. Multivariate analysis was conducted to explore the risk factors influencing the occurrence of portal hypertension and adverse prognosis in patients with cirrhosis. Results: In Group A patients with portal hypertension, we observed lower levels of aspartate aminotransferase, laminin, serum hyaluronic acid, type III procollagen N-terminal peptide, total bile acids, and cholylglycine acid compared to Group B. On the other hand, levels of alanine aminotransferase, white blood cells, and serum albumin were higher in Group A than in Group B. These differences between the groups were statistically significant (P < 0.05). Multivariate analysis of the aforementioned risk factors indicated that low white blood cell count, high cholylglycine acid levels, and high serum hyaluronic acid levels were identified as independent risk factors for the occurrence of difficult-to-control complications in decompensated portal hypertension among patients with liver cirrhosis (P < 0.05). Conclusion: Liver cirrhosis patients with portal hypertension and multiple risk factors like low white blood cell count and high liver transaminase levels should be cautious regarding the progression of portal hypertension when combined with splenomegaly, liver fibrosis, and bile stasis, as it often indicates a poor prognosis. Keywords: portal hypertension, white blood cells, glycine cholate, serum hyaluronic acid According to statistics, the number of patients with chronic liver diseases in China, including chronic hepatitis, fatty liver, and cirrhosis, may exceed 447 million in 2020. Cirrhosis, as a major cause of morbidity and mortality in hepatic diseases, affects over 120 million people worldwide. 1 Decompensated cirrhosis serves as a turning point in the prognosis, primarily manifested by complications such as ascites, hepatic encephalopathy, spontaneous bacterial peritonitis, or variceal bleeding. Accurate staging of decompensated cirrhosis can significantly reduce the risk of mortality. 2 Measurement of HVPG is considered the gold standard for assessing portal hypertension, with HVPG ≥ 16 mm Hg indicating a higher likelihood of refractory complications. 3 Although there have been numerous studies on the risk factors for decompensated cirrhosis in patients with liver cirrhosis, there is a paucity of research focused on the risk factors for decompensated cirrhosis with concomitant portal hypertension. In this study, we conducted a retrospective analysis of clinical data from 60 patients with decompensated cirrhosis from our hospital and People's Hospital of Qu fu City. By employing univariate and multivariate logistic regression analysis, we aimed to identify the risk factors for rebleeding in these patients. In this retrospective analysis, we selected patient records meeting our study criteria from the inpatient electronic case systems at Qingdao Sixth People's Hospital and Qu fu Municipal Hospital. All particip -Abstract Truncated-

Risk factors and prognostic impact of new decompensated events in hospitalized patients with decompensated cirrhosis

Acute Decompensation Events Differentially Impact the Risk of Nosocomial Infections and Short-Term Outcomes in Patients with Cirrhosis

Establishment of Prognostic Scoring Models for Different Etiologies of Acute Decompensation in Hospitalized Patients with Cirrhosis

[Clinical Features and Prognosis of Decompensated Hepatitis C Virus Related Cirrhosis].

A Modified Prognostic Score for Critically Ill Patients with Cirrhosis: an Observational Study.

The Clinical characteristics and prognosis of patients with decompensated schistosomiasis cirrhosis or decompensated alcoholic cirrhosis in ICU

Analysis of Factors Influencing Prognosis and Assessment of 60 Cases of Decompensated Cirrhotic Patients with Portal Hypertension

Association of echocardiography-related parameters with the prognosis of decompensated cirrhosis: a retrospective cohort study

Distinct on-treatment HCC risks associated with different decompensation events in HBV patients with cirrhosis

Prevalence and Clinical Significance of Portal Vein Thrombosis in Patients With Cirrhosis and Acute Decompensation

Interobserver Agreement for Classifying Infections in Patients with Decompensated Cirrhosis Based on Centers for Disease Control and Prevention Criteria

Discharge Outcomes of Hospitalized Patients with New Onset Decompensated Cirrhosis

Outcome of individuals with alcoholic cirrhosis hospitalized with first decompensation and their predictors

The Clinical Course of Cirrhosis Patients Hospitalized for Acute Hepatic Deterioration: A Prospective Bicentric Study.

Community- or Healthcare-Associated Bacterial Infections Increase Long-Term Mortality in Patients With Acute Decompensation of Cirrhosis.

Cardiac dysfunction in patients with cirrhosis and acute decompensation

Comorbid chronic diseases and survival in compensated and decompensated cirrhosis: a population-based study

Increased Delayed Mortality in Patients with Acute‐on‐chronic Liver Failure Who Have Prior Decompensation

Poor Outcomes of Cirrhosis due to Nonalcoholic Steatohepatitis Compared With Hepatitis B After Decompensation With Ascites

Prevalence, clinical characteristics, and outcomes of spontaneous portosystemic shunt in patients with hepatitis B-related cirrhosis: A multicenter study from China

Acute decompensation of cirrhosis versus acute‐on‐chronic liver failure: What are the clinical implications?